Ruxolitinib was found to be more cost-effective than the best available therapy (BAT) when the willingness-to-pay threshold for payers was at $150,000 and applied to patients with hydroxyurea resistant/intolerant polycythemia vera (PV) without splenomegaly, according to a new study.
Ruxolitinib for the treatment of hydroxyurea resistant/intolerant polycythemia vera (PV) without splenomegaly is considered cost-effective compared with the best available therapy (BAT) when a payer’s willingness to pay threshold is at $150,000 per quality-adjusted life year (QALY) gained.
PV is a rare blood cancer characterized by an abnormal red blood cell increase that is caused by a Janus kinase 2 (JAK2) gene mutation. Hydroxyurea chemotherapy resistance or intolerance occurs in 15% to 24% of patients with PV, according to study results presented at the recent Virtual ISPOR 2020 conference.
When the willingness-to-pay threshold was at $150,000, the probability that ruxolitinib was most cost-effective was 73%. Researchers chose this threshold because Institute for Clinical and Economic Review standards depict that costs per QALY and adopting thresholds should be between $100,000 and $150,000.
“These thresholds are commonly cited in US economic analyses. The higher threshold is commonly used for rare conditions, such as [PV],” said Sam Hong, PharmD, co-author and CHOICE fellow at the School of Pharmacy at the University of Washington in Seattle.
The researchers used a 3-state Markov model (hematocrit control, no hematocrit control, and death) to analyze a 15-year period in which 3-month cycles of treatment were used to estimate the economic and health-related quality of life impact of ruxolitinib versus BAT. Costs and outcomes were discounted by 3% annually. The phase 3 RESPONSE-2 trial provided the clinical data, and the published literature were sourced for the cost, utility, and overall survival data.
Investigators found that patients taking ruxolitinib accumulated a mean of 28.5 QALYs (95% CI, 24.9-30.6), resulting in an additional 1.2 QALYs (95% CI, 0.5-2.8) compared with those accumulated by patients in the BAT group, who gained a mean of 27.3 QALYs (95% CI, 23.7-27.0).
Mean total costs for the ruxolitinib arm were $526,100 (95% CI, $428,700-$623,800) compared with $371,700 (95% CI, $310,800-$381-600) for the BAT arm. The mean incremental cost effectiveness ratio (ICER) was $128,600 (95% CI, $82,700-$215,400).
The ICER was most sensitive to change when individual variations were applied to the efficacy of ruxolitinib, the cost of ruxolitinib, and the control state of red blood cell volume.
Previous studies have shown ruxolitinib, a JAK 1/2 inhibitor, to have 7.3 times greater odds (95% CI, 3.4-15.5) than BAT in achieving red blood cell volume control in patients with PV who are resistant or have an intolerance to hydroxyurea.
“Our results suggest ruxolitinib is cost-effective when compared to best available therapy in patients with hydroxyurea resistant/intolerant PV without splenomegaly using a WTP threshold of $150,000/QALY,” the authors concluded.
They noted, however, that additional research is needed to define health state utility values specific to patients with PV and to establish an appropriate surrogate endpoint for survival.
Reference
Hong S, Veenstra DL. Cost-utility analysis of ruxolitinib versus best available therapy for the treatment of hydroxyurea resistant/intolerant polycythemia vera without splenomegaly in the United States. Presented at: Virtual ISPOR 2020; May 18-20, 2020. https://www.ispor.org/heor-resources/presentations-database/presentation/intl2020-3182/99498
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More